tbuckley/cabot-search huggingface dataset:
Psychotherapie bei organischen Erkrankungen.
Authors: Fritz Mohr
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MGMT promoter methylation status in newly diagnosed glioblastomas: Retrospective analysis from a clinical series of patients
Authors: M. Martinez Garcia, A. Tortosa, X. Maldonado, S. Gonzalez, C. Balañá, O. Gallego, N. Viñolas, R. Fuentes, V. Navarro, M. Gil
Journal: Journal of Clinical Oncology (2008)

13021 Background: Current standard treatment of newly diagnosed GBM is radiotherapy (RT) with concurrent Temozolomide (TMZ), followed by TMZ according to the EORTC/NCIC trial. MGMT promoter methylation status has been correlated with prolonged overall survival (OS) and survival benefit from treatment with TMZ and RT. The aim of our study is to assess the efficacy of this schedule in a cohort of patients (pts) out of a trial, and the prognostic implication of the MGMT methylation status in the same unselected population. Methods: From March 2002 to December 2005 89 pts were reviewed from 8 centers. A Kaplan Meier method and a multivariate analysis (MA) using the Cox model were performed to study the time to progression (TTP) and OS. DNA was available from paraffin in 71 samples. DNA was modified with bisulfit, and methylation specific PCR (MSP) was performed. MGMT promoter methylation status was assessed in 62 (69%) pts. Results: Median age 57 years(y) (18–80). 61,8% males. Complete resection (CR) in 33,7%, partial resection (PR) 48,3% and biopsy (B) 18%. Median Karfnosky (IK)90% (40–100). 58% needed dexamethasone (DXM) during RT. 92,1% completed RT-TMZ. 80,9% started adjuvant TMZ. 40,4% completed 6 cycles. Median number of cycles: 4. Median follow up 23 months(m). TTP: 6,9m (CI: 5,4–8,5). In the MA extend of surgery (RR CR vs PR: 1,43 (CI:0,83–2,43) and RR CR vs B: 2,22 (CI: 1,14–4,3)) and age >60y(RR 1.88 CI:1.17–3.04) were significant for recurrence. Median OS: 13,6m (CI 12.1–15.2). DXM treatment RR=1.96 (IC: 1.1–3.4) and >60y RR=1.94 (IC: 1.15–3.28) were significant in the MA for survival. No statistical difference was seen for gender, IK. MGMT methylation: 45,2%. Median survival for patients with methylated MGMT: not reached. Median survival for unmethylated: 12,5m. (p 0,029). No statistical difference was found in TTP according to methylation of MGMT (p 0,6). Conclusions: OS and TTP of this pts were similar to the EORTC/NCIC trial. Determination of methylation of MGMT is feasible and reproducible in the clinical practice. The % of methylation that we found is similar to previously reported. Methylated MGMT is a favourable prognostic factor for OS. Age> 60y and extend of surgery are prognostic factors for PFS, while DXM and age are for OS. No significant financial relationships to disclose.
MEDICAL ACTIVITIES OF THE AUGMENTED MILITARY FORCES
Authors: James C. Magee
Journal: Annals of Internal Medicine (1941)

Article1 June 1941MEDICAL ACTIVITIES OF THE AUGMENTED MILITARY FORCESJAMES C. MAGEE, F.A.C.P.JAMES C. MAGEE, F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-14-12-2173 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONIn the course of my talk to you today I shall discuss the broad aspects of the task confronting the Medical Department in the expansion of medical facilities to provide for the hospitalization of the augmented military forces and for training of its own personnel. I ask you to bear constantly in mind that my discussion must, of necessity, deal with policies and doctrines enunciated in the Military Program of 1940-41 and covers Medical Department activities as they now exist and before the present "limited emergency" changes.GENERAL CONSIDERATIONSFrom the first phase of any expansion in the military... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: U. S. ARMY Washington, D. C.*Read at the Boston meeting of the American College of Physicians April 24, 1941. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1941Volume 14, Issue 12Page: 2173-2178KeywordsArmed forcesHospitalizations Issue Published: 1 June 1941 PDF downloadLoading ...
Abstract 14693: Novel Microfluidic Platform for Point of Care Hypercoagulability Panel Testing
Authors: Sirisha Emani, Rama Sista, Hugo Loyola, Vamsee Pamula, Sitaram M Emani
Journal: Circulation (2010)

Introduction: Point-of-care diagnostic testing for hypercoagulability panel has potential to improve risk stratification and management of patients with cardiovascular diseases, but has been limite...
Abstract 110: Importance of Mechanical Circulatory Support and Immediate Reperfusion of Occluded Coronary Artery in Patients with Acute Coronary Syndrome and Metabolic Phase of Ventricular Fibrillation
Authors: Hiroyuki Hanada, Takumi Higuma, Naoki Abe, Shin Saito, Masahiro Yamada, Ken Okumura
Journal: Circulation (2007)

Spontaneous circulation can not be obtained only by electrical shocks when ventricular fibrillation (VF) persisted for >10 minutes. This is referred as a metabolic phase, but the effective treatmen...
Abstract 2345: Does Myocardial Perfusion Imaging During Dobutamine Stress Echocardiography Provides Incremental Prognostic Information In Women With Suspected Coronary Artery Disease?
Authors: Melda S Dolan, Michelle Bierig, Bassel Beitinjaneh, Swathy Kolli, Samir Baroudi, Bernard Chaitman, Arthur J Labovitz
Journal: Circulation (2006)
Bridges' Dietetics For The Clinician.
Authors: Harry J. Johnson
Journal: Annals of Internal Medicine (1950)

The fifth edition of this useful book on dietary management retains the general form of previous editions with some sections extensively revised and others largely unchanged. Part I deals with general considerations of digestion and with the classification, structure and constituents of foods. In one chapter, foods which have high and low concentrations of specific nutrient factors, e. g., cholesterol, iron, purines and individual vitamins, are listed in tabular form. This section has been revised in accordance with recent knowledge of the distribution of nutrients in foods and is extremely useful. It is regrettable that the chapter on vitamins has not also been subjected to considerable revision. While some changes have been made, most of the references are to studies conducted prior to 1940. A chapter on supplementary methods of feeding might be improved by the addition of a section on parenteral nutrient therapy. Part II of this book deals
A Gynecologic Oncology Group study of frequent copy number aberrations in African American versus Caucasian women with stage I versus stage IIIC/IV endometrioid endometrial cancer
Authors: C. Morrison, D. Gaile, K. Darcy, S. Liu, L. Shepherd, D. Cohn, S. McMeekin, N. Nowak, L. Maxwell
Journal: Journal of Clinical Oncology (2009)

e16501 Background: An array-based comparative genomic hybridization (aCGH) analysis was performed to determine if frequent (&gt;40%) copy number aberrations (CNAs) exist in African American (AA) versus Caucasian (C) women with stage I versus stage IIIC/IV endometrioid endometrial cancers (EEC). Methods: Tumor DNA was isolated from 80 frozen primary tumors from the GOG-210 protocol. RPCI 19K BAC arrays were hybridized (GeneTAC HybStation) and scanned (Gene Pix 4200AL Laser Scanner). Spot fluorescence values were quantified using ImaGene, vetted for quality and loess corrected with adjustments for chip-specific spatial effects. The genome was segmented to identify regions with common copy number means (DNAcopy software). Posterior aberration probabilities for the regions were obtained using CGHcall and data was visualized and annotated using iGenomicViewer in R. Validation will be performed by fluorescence in situ hybridization using select BAC probes and endometrial cancer tissue microarrays (TMAs) with either 400 cases linked with clinical, treatment and outcome data or 180 AA versus 120 C women from GOG-136. Results: Recurrent CNAs were identified in all stage and race groups. Distinct genomic losses and gains were observed that appear to segregate Caucasian women with stage I disease from African American women with stage I disease and African American or Caucasian women with stage IIIC/IV disease. Conclusions: The GOG-210 bank yielded high quality DNA for detecting and mapping CNAs in frozen primary tumors with high resolution. Our results would imply that racial disparity for AA EEC has a genetic basis regardless of stage. Validation studies are currently underway in two endometrial cancer TMAs. [Table: see text] No significant financial relationships to disclose.
Abstract 16224: Ghost Struts: A New IV-OCT Artifact
Authors: David Halaney, J. Jacob Mancuso, Derek Ho, Tianyi Wang, Sahar Elahi, Jouke Dijkstra, Thomas E Milner, Marc D Feldman
Journal: Circulation (2013)

Background: We studied the mechanisms underlying two intravascular optical coherence tomography (IV-OCT) artifacts, Merry-Go-Round (MGR) - an increase in strut arc length (SAL) - and Blooming - an ...
Serum Proteins in Health and Disease.
Authors: Georges Sandor
Journal: Annals of Internal Medicine (1968)

However, the authors have tried to provide a guide to BILIRUBIN METABOLISM Edited by I. A. D. Bouchier and metabolic biochemistry, and also a selected textbook of Barbara H. Billing.(Pp.xii + 294; illustrated. 63.) metabolic diseases.Because of the limited space available Oxford and Edinburgh: Blackwell Scientific Pub- this has led to over-simplification, and such topics as lications.1967.liverfunction tests, plasma protein synthesis, and acid-base Progress in the study of bilirubin metabolism has been balance would better be studied from more specialized rapid in the last 10 years though limited by the very texts.On acid-based balance, for example, the sole use difficult analytical and other techniques.Thus routine of the Astrup nomenclature and derivations may be measurement of unlabelled bilirubin still depends upon found jarring by those more familiar with other ways of modifications of the Van den Bergh diazo reaction with considering the controversial problems of acid-base the conjugated and unconjugated pigment and the calculations and terminology.
Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies
Authors: S. Pacey, R. E. Plummer, G. Attard, C. Bale, A. H. Calvert, S. Blagden, N. L. Fox, A. Corey, J. S. de Bono
Journal: Journal of Clinical Oncology (2005)

3055 Background: HGS-ETR2 is a fully-human high affinity monoclonal antibody specific and agonistic to the Tumor Necrosis Apoptosis Inducing Ligand (TRAIL) Receptor 2. HGS-ETR2 mediates apoptosis by binding to TRAIL-R2, leading to activation of the extrinsic apoptosis pathway. Human tumor xenograft models show tumor regression in response to HGS-ETR2 at doses of 2.5 mg/kg or lower. Methods: Patients with advanced solid tumors were treated with HGS-ETR2 IV once every 21 days. Results: Currently 22 patients have received 73 courses of HGS-ETR2 over 5 dose levels ranging from 0.1 to 10 mg/kg. The majority (20/22) received at least 2 courses (range 1 - 13). One patient experienced an asymptomatic grade 3 elevation of serum amylase at 1 mg/kg detected at course 1 day 15 with a peak amylase of 423 u/L (3.4 x ULN) while receiving concomitant ciprofloxacin; no other patients have experienced dose-limiting toxicity. One subject with hepatocellular carcinoma and extensive hepatic metastases experienced grade 3 transient transaminitis at 3 mg/kg during Cycle 5 which resolved by Cycle 6, and went on to receive a further course with no enzyme changes. To date, stable disease (= 2 cycles) has been observed in seven subjects (range 2–13). HGS-ETR2 pharmacokinetics are linear across a 100-fold dose range, from 0.1 to 10 mg/kg, and at the 10 mg/kg dose are characterized by a mean (SD) t1/2,z of 15 (4) days, CL of 4.79 (2.30) mL/day/kg, and V1 of 51 (5) mL/kg, which is slightly larger than the plasma volume. The 1.7-fold larger Vss of 87 (7) mL/kg indicates that HGS-ETR2 distributes outside the plasma volume. Human anti-human antibody formation has not been detected. Conclusions: HGS-ETR2, a specific TRAIL R2 targeting agent, can be safely administered IV every 3 weeks at doses that reach plasma concentrations associated with activity in preclinical models. Further evaluation in Phase II trials is warranted. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Human Genome Sciences Human Genome Sciences Human Genome Sciences Human Genome Sciences
Effects of Donor Pre-Treatment With Dopamine on Survival After Heart Transplantation
Authors: Urs Benck, Simone Hoeger, Paul T. Brinkkoetter, Uwe Gottmann, Duygu Doenmez, Detlef Boesebeck, Werner Lauchart, Jan Gummert, Matthias Karck, Hans B. Lehmkuhl, Hartmuth B. Bittner, Andreas Zuckermann, Florian Wagner, Uwe Schulz, Achim Koch, Amir K. Bigdeli, Christoph Bara, Stephan Hirt, Michael Berchtold-Herz, Stefan Brose, Ulf Herold, Johannes Boehm, Henryk Welp, Thomas Strecker, Andreas Doesch, Rainer Birck, Bernhard K. Krämer, Benito A. Yard, Peter Schnuelle
Journal: Journal of the American College of Cardiology (2011)
Epidemiology of human cryptosporidiosis in Ireland, 2004-2006: analysis of national notification data
Authors: P Garvey, P McKeown
Journal: Eurosurveillance (2009)

Since cryptosporidiosis became a notifiable human disease in 2004 in Ireland, evidence has been growing as to the national burden of illness caused by this pathogen. Nationally, crude incidence rates of between 8.7 and 13.4 per 100,000 were reported annually in the period 2004-2006.
Abstract 16056: Acute HIF Prolyl Hydroxylase 2 Inactivation Confers Protection Against Myocardial Ischemic Reperfusion Injury
Authors: Steven M Bair, Yoji A Minamishima, Ronglih Liao, William G Kaelin, Javid Moslehi
Journal: Circulation (2011)

Background: How cardiomyocytes respond to hypoxia is a fundamental question in cardiovascular biology and relevant to many clinical phenomena including ischemic preconditioning. Hypoxia-Inducible F...
HIF-1α pathway: role, regulation and intervention for cancer therapy
Authors: Georgina N. Masoud, Wei Li
Journal: Acta Pharmaceutica Sinica B (2015)

Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer drug target. Many recent studies have provided convincing evidences of strong correlation between elevated levels of HIF-1 and tumor metastasis, angiogenesis, poor patient prognosis as well as tumor resistance therapy. It was found that hypoxia (low O2 levels) is a common character in many types of solid tumors. As an adaptive response to hypoxic stress, hypoxic tumor cells activate several survival pathways to carry out their essential biological processes in different ways compared with normal cells. Recent advances in cancer biology at the cellular and molecular levels highlighted the HIF-1α pathway as a crucial survival pathway for which novel strategies of cancer therapy could be developed. However, targeting the HIF-1α pathway has been a challenging but promising progresses have been made in the past twenty years. This review summarizes the role and regulation of the HIF-1α in cancer, and recent therapeutic approaches targeting this important pathway.
Abstract 1311: Mipomersen, a First-in-Class Apo-B Synthesis Inhibitor, Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia: Results of a Phase III Study
Authors: Frederick Raal, Raul Santos, Dau-Ming Niu, Robin H Lachmann, Daniel Gaudet, Ju Le Tan, William C Cromwell, David Marais, Diane L Tribble, Joann D Flaim, Stanley T Crooke
Journal: Circulation (2009)
Predictors of adjuvant chemotherapy (AT) decision-making in referred patients (pts) with stage II and III colon cancer (CC)
Authors: D. S. Ksienski, M. Levesque, S. Gill
Journal: Journal of Clinical Oncology (2009)

e15070 Background: Randomized clinical trials have demonstrated a robust survival benefit of AT for node positive (stage III) CC patients; similar evidence for node-negative (stage II) patients is lacking. While guidelines recommend AT for stage III colon cancer but AT is not a routine recommendation for stage II. Actual practice of the evidence varies and suggests the interplay of additional variables. We sought to identify factors associated with practice patterns which vary from conventional AT guidelines, ie no AT in stage III CC and receipt of AT in.stage II CC. Methods: Data pertaining to pt demographics, tumor characteristics, and treatment for pts with resected stage II (n=176) and III CC (n=235) referred to the British Columbia Cancer Agency in 2004 was collected by retrospective chart review. One-sided Fisher's exact test was used to assess statistical significance (p&lt;0.05) by univariate analysis. Results: 28% (n=49) of stage II pts received AT. Compared to untreated pts, stage II pts who received AT were significantly more often younger than 66 years (57% vs 21%), lived in a city with a regional cancer center (71% vs 51%), had T4 disease (33% vs 9%), vascular invasion (22% vs 5%), perineural invasion (10% vs 2%) and high grade (26% vs 2%). Marital status, ethnicity, lymphatic invasion and high CEA were not associated with AT in stage II. 29% (n=69) of stage III pts did not receive AT. Compared to treated pts, stage III pts who did not receive AT were significantly more often older than 65 years (91% vs 51%), had low grade disease (96% vs 84%) and presented for oncology consultation greater than 42 days from surgery (29% vs 11%). Marital status, ethnicity, residence, T4 status or N2 status were not associated with no AT in stage III. Conclusions: For pts with stage II CC, subgroups associated with high risk for relapse were more likely to receive AT although the majority of stage II pts in this cohort remained untreated. For stage III disease, almost one-third of referred pts did not receive AT. Older age and delayed presentation were strongly associated with failure to receive AT. Within the limitations of a retrospective review, these data highlight the significant and commonly observed implications of factors other than stage in AT decision-making for high risk resected CC. No significant financial relationships to disclose.
Cold Injury: Transactions of the First Conference June 4-5, 1951, New York, New York
Authors: M. Irene Ferrer
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Experiments on Myself. Memoirs of a Surgeon in Germany.
Authors: Werner Forssmann
Journal: Annals of Internal Medicine (1975)

Much has been written on children of the nineteenth-century British industrial labouring class, dwelling in city slums, exploited by unscrupulous masters, and immortalized by Charles Dickens.Far less is known of their contemporaries in the country, despite the fact that agricultural labourers comprised in 1837 the largest group of workers in England, and that by 1851 they made up one-fifth of the nation's adult work-force.Mrs. Horn's purpose is to trace the day-to-day experiences of the children of farm workers and village craftsmen, and she deals mainly with the 1880s and 1890s, restricting herself topographically mainly to the South Midlands.Remembering childhood holidays in the country, one imagines that the country child was in all ways better off than his town counterpart.However, his advantages were marginal because he was living under equally primitive and insanitary conditions, and was assailed by both compulsory schooling and parental exploitation in the fields or in local cottage industries.But parents and employers were usually willing to sacrifice education so that the child could be rendered economically viable at the earliest possible age.One of the most interesting features of this process is that exactly the same had happened to town children several decades earlier.It had been resolved by means of reforms, yet identical evils still existed, now transferred to the country.Up till now this striking fact has been little appreciated.The author draws her material from a number of primary sources, especially school logs, and from secondary literature.The appendices contain details of housing, diet, household economics, accounts of personal experiences, and reports on rural activities.Some amount of oral history has been employed, and this, together with the manuscript material used, tends to concentrate the study on Oxfordshire and neighbouring counties, although the same conditions were presumably countrywide.Chapter ten deals with 'Sickness and its cure'.In it the medical, hygienic, thera- peutic and prophylactic aspects of the country child are discussed adequately and accurately.The common disorders are mentioned, but not rickets.It would be interesting to know if greater exposure to sunlight made it less common than in the town child, who had an equally rachitic diet.Mrs. Horn's book is an important addition to the history of the child, for she has surveyed a previously neglected, large group, and has produced an excellent scholarly and well-illustrated account replete with information, much of it original.There is at the moment an increasing interest in the history of paediatrics, and this book as a contribution to it can be recommended enthusiastically.
Abstract 842: Release of Tissue Plasminogen Activator (t-PA) in Response to Ischemia and Reactive Hyperemia is Mediated by P2Y1 Receptors
Authors: Goran K Olivecrona, Matthias Gotberg, Jan Harnek, Kenneth A Jacobson, Sverker Jern, David Erlinge
Journal: Circulation (2006)

Background: The endothelial P2Y1 receptor is responsible for a large part of reactive hyperemia following cardiac ischemia. Tissue plasminogen activator (t-PA) increases during reactive hyperemia. ...